Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
NCT01260844 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2011-10-21
Summary
Phase 1, drug-drug interaction study to evaluate the effects of Briakinumab on hte pharmacokinetics of single doses of CYP substrate in subjects with moderate to severe psoriasis.
Conditions
Interventions
- DRUG
-
briakinumab
single dose briakinumab and 2 doses of CYP substrates
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
David A Williams, MD · Abbott
Study Design
- Allocation
- NON_RANDOMIZED
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-04-30
More Related Trials
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
NCT00848055 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
NCT03922607 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
NCT01736696 ·Status: COMPLETED ·Phase: PHASE1
-
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02694523 ·Status: COMPLETED ·Phase: PHASE3
-
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
NCT01577550 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
NCT00604682 ·Status: COMPLETED ·Phase: PHASE2
-
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
NCT04999839 ·Status: COMPLETED ·Phase: PHASE2
-
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
NCT01855880 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03598790 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT03591887 ·Status: COMPLETED ·Phase: PHASE2
-
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT03463187 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis
NCT03337022 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00237887 ·Status: COMPLETED ·Phase: PHASE3
-
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
NCT01937260 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
NCT01708590 ·Status: TERMINATED ·Phase: PHASE3
-
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645814 ·Status: COMPLETED ·Phase: PHASE2
-
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03000075 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645892 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
NCT01988103 ·Status: COMPLETED ·Phase: PHASE2
-
Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis
NCT00824980 ·Status: UNKNOWN ·Phase: PHASE2
-
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02684357 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
NCT01412944 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035
NCT02690142 ·Status: COMPLETED ·Phase: PHASE1
-
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
NCT02672852 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
NCT00396422 ·Status: COMPLETED ·Phase: PHASE2